About Sheila Gujrathi
Sheila Gujrathi is a director at BlossomHill Therapeutics.
Form D filings name Sheila Gujrathi as a director at ADARx Pharmaceuticals.
Sheila Gujrathi reports to the SEC as a director or officer of 8 public companies, including Processa Pharmaceuticals (PCSA), Ventyx Biosciences (VTYX) and Janux Therapeutics (JANX).
Sheila Gujrathi first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name Sheila Gujrathi in the role, so the role may have started earlier or lasted longer.
BI
PI
Processa Pharmaceuticals, Inc.
Director
2026 · Public company (PCSA)
VI
Ventyx Biosciences, Inc.
Director
2021 – 2026 · Public company (VTYX)
JI
Janux Therapeutics, Inc.
Director
2021 – 2025 · Public company (JANX)
TI
Turning Point Therapeutics, Inc.
Director
2019 – 2020 · Public company (TPTX)
GI
Gossamer Bio, Inc.
President & CEO, director
2019 – 2020 · Public company (GOSS)
FI
Five Prime Therapeutics, Inc.
Director
2015 – 2018 · Public company (FPRX)
RI
Receptos, Inc.
Chief Medical Officer
2013 – 2015 · Public company (RCPT)
Key Colleagues at Startups
The people Sheila Gujrathi works with at each company, as listed on that company's latest Form D.
ADARx Pharmaceuticals, Inc. · Form D, Aug 10, 2023
RZ
Rui Zhu
Executive officer
SG
Simeon George
Director
JL
Judith Li
Director
Erez Chimovits
Director
ZL
Zhen Li
President and Chief Executive Officer, director
YS
Yuan (Eliza) Sun
Director
CY
Chen Yu
Director
RS
Ricky Sun
Director
LK
Lorence Kim
Director
CG
Carl Gordon
Director